Conference
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC)
Abstract
13015
Background: Despite initial responses to chemotherapy, median survival in HRPC remains a dismal 18 mos. Novel therapeutic approaches are clearly needed. The enzyme ribonucleotide reductase (RNR) composed of 2 subunits, R1 and R2 is essential for DNA synthesis and repair. The R2 subunit is often overexpressed in tumors increasing their malignant potential and promoting drug resistance. GTI-2040 (Lorus Therapeutics, …
Authors
Sridhar SS; Canil CM; Hotte SJ; Chi K; Ernst S; Pond GR; Dick C; Zwiebel JA; Moore MJ
Volume
24
Pagination
pp. 13015-13015
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 20, 2006
DOI
10.1200/jco.2006.24.18_suppl.13015
Conference proceedings
Journal of Clinical Oncology
Issue
18_suppl
ISSN
0732-183X